Company
Evive Biotech is a global biologics company focused on oncology, inflammatory and metabolic diseases. As the first biopharmaceutical company to build a platform bringing innovative therapies from China to the world, we adopt a holistic approach to drug development, combining exceptional research and commercialization capabilities with our world-class in-house regulatory expertise and extensive international management experience.
Mission
Revolutionary remedies for a healthy and happy world.
Vision
Developing innovative medicines for patients worldwide.
Values
Entrepreneurial
Value-driven
Integrity
Validation
Excellence
What’s Going On
Our innovative assets have recently achieved significant milestones, including the completion of F-627's global Phase III clinical trials, which met its primary and secondary endpoints, the BLA submission of F-627 to the US FDA, and the receipt of orphan drug designation from the US FDA for F-652. We are engaging with potential partners and the broader scientific community to share our successes and to ensure broad access to treatment options for patients.
PLOS ONE Article Details IL-22’s Critical Role in Mitigating ARDS
- 12 November 2021
Evive Biotech Announces the Grand Opening of EWING R&D Center in San Francisco Bay Area
- 3 November 2021
Evive Biotech Announces the Appointment of Mr. Denny Hou as VP, Global Medical Research
- 28 October 2021
Evive Biotech Announces the Appointment of Dr. Kaiming Sun as VP, Clinical Biomarker
- 26 October 2021
Evive Biotech Announces the Appointment of Dr. Simon Li as Executive VP, Chief Medical Officer
- 15 October 2021
Evive Biotech Announces the Appointment of Dr. Jing Wang as VP, Clinical Pharmacology
- 12 October 2021
